Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings.

ABSTRACT:

Background

Following testing in clinical trials, the use of remdesivir for treatment of COVID-19 has been authorized for use in parts of the world, including the USA and Europe. Early authorizations were largely based on results from two clinical trials. A third study published by Wang et al. was underpowered and deemed inconclusive. Although regulators have shown an interest in interpreting the Wang et al. study, under a frequentist framework it is difficult to determine if the non-significant finding was caused by a lack of power or by the absence of an effect. Bayesian hypothesis testing does allow for quantification of evidence in favor of the absence of an effect.

Findings

Results of our Bayesian reanalysis of the three trials show ambiguous evidence for the primary out

SUBMITTER: Hoek JM 

PROVIDER: S-EPMC8301659 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature